查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1888753

美国白血病药物市场规模、份额和趋势分析报告：按类型、治疗方法、分销管道和细分市场预测（2025-2033 年）

U.S. Leukemia Therapeutics Market Size, Share & Trends Analysis Report By Type (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)), By Treatment, By Distribution Channels, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国白血病药物市场摘要

据估计，2024年美国白血病药物市值为72.3亿美元，预计到2033年将达到130.7亿美元。

预计从 2025 年到 2033 年，该行业将以 6.80% 的复合年增长率成长。标靶治疗因其临床精准度高而日益普及，这是推动该行业成长的主要因素。

基因组分析技术的广泛应用有助于精准选择治疗方法，并提升整体治疗效果。 CAR-T细胞疗法的日益普及，透过提高高风险患者的缓解期持久性，推动了市场成长。双特异性抗体的进步也为復发和难治性病例提供了更多治疗选择。例如，根据美国国家癌症研究所（透过监测、流行病学和最终结果计画）2024年3月发布的报告，截至2022年，美国预计将有536,245名白血病患者，显示该疾病的盛行率很高。分子诊断技术的广泛应用有助于识别适合接受先进治疗方法的患者。新一代药物的持续研发也维持了市场成长动能。人们对个人化癌症治疗日益增长的需求，预计将进一步增强对治疗的长期需求。

随着临床研发管线为急性和慢性白血病提供新的作用机制，治疗方法推动了市场成长。口服标靶药物的日益普及提高了患者的依从性，从而支撑了强劲的商业性表现。不断扩大的临床证据增强了主要肿瘤医疗网络中处方医生的信心。存活率的提高带来了维持治疗和后续治疗的持续需求。人口老化带来的高疾病负担推动了多种类型白血病治疗的启动。联合治疗的进展提高了治疗第一线和挽救治疗的疗效深度。例如，根据 Business Wire 报告，2025 年 11 月，美国食品药物管理局(FDA) 授予 Leukogene Therapeutics Inc. 的主要候选产品 LTI-214（也称为 M2T-CD33）孤儿药资格，用于治疗急性骨髓性白血病(AML)。这为合格的临床试验费用核准了税额扣抵，免除了部分 FDA 费用，并在核准后享有美国市场独占权。大型製药企业的积极投资正在加速新药的研发和商业化。

美国癌症专科治疗中心的普及提高了患者获得治疗的机会，促进了市场扩张。真实世界数据（RWE）的累积推动了免疫疗法和标靶治疗的广泛应用。高价值生物製剂的利用率不断提高，增强了主要製药厂商的收入贡献。治疗反应持久性的增加降低了復发率，并有助于长期持续治疗。主要癌症机构临床试验活动的活性化，促进了新兴治疗平台的快速评估。对精准治疗路径的日益重视，推动了先进疗法的稳定应用。患者管理方法的不断改进，增强了对白血病治疗的持续需求。

目录

第一章调查方法和范围

第二章执行摘要

第三章美国白血病药物市场变数、趋势与范围

  • 市场谱系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章美国白血病药物市场：按类型分類的业务分析

  • 按类型分類的市场份额（2024 年和 2033 年）
  • 按类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 慢性骨髓性白血病（CML）
  • 慢性淋巴性白血病（CLL）
  • 急性淋巴性白血病（ALL）
  • 急性骨髓性白血病（AML）
  • 其他的

第五章美国白血病药物市场：按疗法分類的业务分析

  • 按疗法分類的市场份额（2024 年和 2033 年）
  • 按治疗方法分類的市场规模、预测和趋势分析（2021-2033 年）
  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 其他的

第六章美国白血病药物市场：按分销管道分類的业务分析

  • 按分销管道分類的市场份额（2024 年和 2033 年）
  • 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 医院药房
  • 零售药房
  • 其他的

第七章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Novartis
    • Roche/Genentech
    • AbbVie
    • Bristol-Myers Squibb（BMS）
    • Pfizer
    • Amgen
    • Johnson &Johnson（Janssen）
    • Gilead Sciences（Kite Pharma）
    • AstraZeneca
    • Sanofi
Product Code: GVR-4-68040-808-9

U.S. Leukemia Therapeutics Market Summary

The U.S. leukemia therapeutics market size was estimated at USD 7.23 billion in 2024 and is projected to reach USD 13.07 billion by 2033, growing at a CAGR of 6.80% from 2025 to 2033. The industry is expanding due to the strong adoption of targeted therapies that offer high clinical precision.

Increased use of genomic profiling supports accurate treatment selection and enhances overall therapeutic outcomes. Growth in CAR-T cell therapy utilization adds momentum through improved remission durability in high-risk patients. Advancements in bispecific antibodies strengthen options for relapsed and refractory cases. For instance, in March 2024, the National Cancer Institute (via the Surveillance, Epidemiology, and End Results Program) reported that in the U.S., there were an estimated 536,245 people living with leukemia in 2022, representing the prevalence of the disease. The broader integration of molecular diagnostics enhances patient identification for advanced therapies. Continuous development of next-generation agents sustains momentum in the market. The rising preference for personalized oncology care is expected to strengthen long-term treatment demand.

Therapeutic innovation strengthens market growth as clinical pipelines deliver novel mechanisms for acute and chronic leukemia. Wider availability of oral targeted agents improves adherence and supports strong commercial performance. Expansion of clinical evidence enhances prescriber confidence across major oncology networks. Increased survival rates create ongoing demand for maintenance and follow-up therapies. High disease burden within aging populations drives treatment initiation across multiple leukemia types. Advancements in combination regimens have improved the depth of response in both frontline and salvage settings. For instance, in November 2025, Business Wire reported that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Leukogene Therapeutics Inc.'s lead product candidate LTI-214 (also named M2T-CD33) for the treatment of Acute Myeloid Leukemia (AML), providing incentives such as tax credits on qualified clinical trial costs, waiver of certain FDA fees, and U.S. market exclusivity upon approval. Strong investment from major pharmaceutical companies accelerates the development and commercialization of new agents.

Improved treatment access through specialized oncology centers contributes to market expansion across the U.S. Growth in real-world evidence supports broader adoption of immunotherapy and targeted strategies. Higher utilization of high-value biologics strengthens revenue contribution across leading manufacturers. Enhanced therapeutic durability reduces the frequency of relapse and encourages continued long-term therapy. Rising clinical trial activity in major cancer institutions supports rapid evaluation of emerging platforms. An increased emphasis on precision treatment pathways supports the consistent uptake of advanced therapeutics. Continuous improvements in patient management practices reinforce sustained demand for leukemia treatments.

U.S. Leukemia Therapeutics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. leukemia therapeutics market report based on type, treatment, and distribution channels:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Chronic Myeloid Leukemia (CML)
  • Chronic Lymphocytic Leukemia (CLL)
  • Acute Lymphocytic Leukemia (ALL)
  • Acute Myeloid Leukemia (AML)
  • Others
  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others
  • Distribution Channels Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Distribution Channels
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Leukemia Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Leukemia Therapeutics Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Chronic Myeloid Leukemia (CML)
    • 4.4.1. Chronic Myeloid Leukemia (CML) Market, 2021 - 2033 (USD Million)
  • 4.5. Chronic Lymphocytic Leukemia (CLL)
    • 4.5.1. Chronic Lymphocytic Leukemia (CLL) Market, 2021 - 2033 (USD Million)
  • 4.6. Acute Lymphocytic Leukemia (ALL)
    • 4.6.1. Acute Lymphocytic Leukemia (ALL) Market, 2021 - 2033 (USD Million)
  • 4.7. Acute Myeloid Leukemia (AML)
    • 4.7.1. Acute Myeloid Leukemia (AML) Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Leukemia Therapeutics Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by treatment, 2021 to 2033 (USD Million)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Leukemia Therapeutics Market: Distribution Channels Business Analysis

  • 6.1. Distribution Channels Market Share, 2024 & 2033
  • 6.2. Distribution Channels Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by distribution channels, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Novartis
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Roche / Genentech
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. AbbVie
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Bristol-Myers Squibb (BMS)
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Pfizer
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Amgen
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Johnson & Johnson (Janssen)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Gilead Sciences (Kite Pharma)
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. AstraZeneca
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sanofi
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. leukemia therapeutics market, by Type, 2021-2033, (USD Million)
  • Table 4 U.S. leukemia therapeutics market, by treatment, 2021-2033, (USD Million)
  • Table 5 U.S. leukemia therapeutics market, by distribution channels, 2021-2033, (USD Million)

List of Figures

  • Fig. 1 U.S. leukemia therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 U.S. leukemia therapeutics market dynamics
  • Fig. 12 U.S. leukemia therapeutics market: Porter's five forces analysis
  • Fig. 13 U.S. leukemia therapeutics market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Chronic Myeloid Leukemia (CML) market, 2021 - 2033 (USD Million)
  • Fig. 16 Chronic Lymphocytic Leukemia (CLL) market, 2021 - 2033 (USD Million)
  • Fig. 17 Acute Lymphocytic Leukemia (ALL) market, 2021 - 2033 (USD Million)
  • Fig. 18 Acute Myeloid Leukemia (AML) market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 21 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 22 Targeted Therapy market, 2021 - 2033 (USD Million)
  • Fig. 23 Immunotherapy market, 2021 - 2033 (USD Million)
  • Fig. 24 Others market, 2021 - 2033 (USD Million)
  • Fig. 25 Distribution Channels market, 2021 - 2033 (USD Million)
  • Fig. 26 Hospital Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 27 Retail Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 Company categorization
  • Fig. 30 Company market position analysis
  • Fig. 31 Strategic framework